var data={"title":"Ustekinumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ustekinumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/373510?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ustekinumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ustekinumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9419532\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Stelara</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867209\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Stelara</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867212\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antipsoriatic Agent;</li>\n      <li>\n        Interleukin-12 Inhibitor;</li>\n      <li>\n        Interleukin-23 Inhibitor;</li>\n      <li>\n        Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6868014\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;55 kg: 260 mg as single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;55 kg to 85 kg: 390 mg as single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;85 kg: 520 mg as single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: SubQ: 90 mg every 8 weeks; begin maintenance dosing 8 weeks after the IV induction dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plaque psoriasis:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial and maintenance:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter. <b>Note:</b> Doses of 45 mg given to patients &gt;100 kg were also efficacious; however, 90 mg is the recommended dose in these patients due to greater efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis:</b> SubQ: <b>Note:</b> When used for psoriatic arthritis, may be administered alone or in combination with methotrexate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial and maintenance:</i> 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Coexistent psoriatic arthritis and moderate to severe plaque psoriasis in patients &gt;100 kg:</i> Initial and maintenance: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46146609\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <b> Plaque psoriasis:</b> Children &ge;12 years of age and Adolescents: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;60 kg: 0.75 <b>mg/kg</b> at 0 and 4 weeks, and then every 12 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;60 kg to &le;100 kg: 45 <b>mg </b>at 0 and 4 weeks, and then every 12 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;100 kg: 90 <b>mg </b>at 0 and 4 weeks, and then every 12 weeks thereafter</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867998\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867999\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6868000\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6868009\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stelara: 130 mg/26 mL (26 mL) [contains edetate disodium dihydrate, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stelara: 45 mg/0.5 mL (0.5 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stelara: 45 mg/0.5 mL (0.5 mL); 90 mg/mL (1 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867211\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9419531\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stelara: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125261s138lbl.pdf#page=30&amp;token=7UgPd4N8ghPJVqZcGUtDPjsyptSJDOYgT5pnV6SJDyt7oxnbkdDuhsouuZcdxWAuao2wX7FiuTGrU1NfazWwVJn4jrRy1XSoPy/+YV2U3z0q7A2o4EVHGzByy/9VWV2I&amp;TOPIC_ID=9514\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125261s138lbl.pdf#page=30</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6868005\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over at least 1 hour; use of IV set with an in-line, low-protein binding filter (0.2 micrometer) required. Do not infuse concomitantly in the same IV line with other agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subcutaneous: Administer by subcutaneous injection into the top of the thigh, abdomen, upper arms, or buttocks. Rotate sites. Do not inject into tender, bruised, erythematous, or indurated skin. Avoid areas of skin where psoriasis is present. Discard any unused portion. Intended for use under supervision of physician; self-injection may occur after proper training.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867268\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease:</b> Treatment of moderately to severely active Crohn disease in adults who have failed or were intolerant to immunomodulatory or corticosteroid therapy, but never failed tumor necrosis factor (TNF) blocker therapy or who have failed or were intolerant to treatment with one or more TNF blockers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plaque psoriasis:</b> Treatment of moderate to severe plaque psoriasis in patients &ge;12 years of age who are candidates for phototherapy or systemic therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis:</b> Treatment of active psoriatic arthritis (as monotherapy or in combination with methotrexate) in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867207\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Stelara may be confused with Aldara</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ustekinumab may be confused with infliximab, rituximab</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867984\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (&le;12%; associated with reduced efficacy in psoriasis patients)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (psoriasis: 27% to 72%; severe infection: &le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (Crohn disease: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (psoriasis: 5%), fatigue (psoriasis: 3%), dizziness (psoriasis: 2%), depression (psoriasis: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (2% to 4%), acne vulgaris (Crohn disease: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (Crohn disease: 4%), nausea (psoriatic arthritis: 3%), dental disease (infection; 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal mycosis (Crohn disease: &le;5%), vulvovaginal candidiasis (Crohn disease: &le;5%), urinary tract infection (Crohn disease: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Skin carcinoma (nonmelanoma including squamous cell carcinoma; psoriasis: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Erythema at injection site (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (psoriatic arthritis: 3%), back pain (psoriasis: 2%), weakness (Crohn disease: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (Crohn disease: 5%), sinusitis (Crohn disease: 3%), pharyngolaryngeal pain (psoriasis: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Appendicitis, cholecystitis, gastroenteritis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Perirectal abscess</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Osteomyelitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, bacterial infection, bleeding at injection site, bruising at injection site, cellulitis, diverticulitis, erythrodermic psoriasis, fungal infection, herpes zoster, hypersensitivity reaction, induration at injection site, irritation at injection site, itching at injection site, malignant neoplasm, meningitis due to listeria monocytogenes, ocular herpes simplex, pain at injection site, pustular psoriasis, reversible posterior leukoencephalopathy syndrome, skin rash, swelling at injection site, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867273\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clinically significant hypersensitivity to ustekinumab or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe infections such as sepsis, tuberculosis, and opportunistic infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867274\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: Antibody formation to ustekinumab has been observed with therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity, including anaphylaxis and angioedema, has been reported. Discontinue immediately with signs/symptoms of hypersensitivity reaction and treat appropriately as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: May increase the risk for infections or reactivation of latent infections. Serious bacterial, fungal, and viral infections have been observed with use. Avoid use in patients with clinically important active infection until the infection resolves or is successfully treated. Exercise caution when considering use in patients with a history of new/recurrent infections, with conditions that predispose them to infections (eg, diabetes or residence/travel from areas of endemic mycoses), with chronic, latent, or localized infections, or who are genetically deficient in IL-12/IL-23 (IL-12/IL-23 genetic deficiency may predispose patients to disseminated infection). Patients who develop a new infection while undergoing treatment should consult their health care provider and be monitored closely. If a patient develops a serious infection, therapy should be discontinued or withheld until successful resolution of infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: May increase the risk for malignancy although the impact on the development and course of malignancies is not fully defined. Rapidly appearing cutaneous squamous cell carcinomas (multiple) have been reported in patients receiving ustekinumab who were at risk for developing nonmelanoma skin cancer. Monitor all patients closely for the development of nonmelanoma skin cancer; closely follow patients &gt;60 years of age, with a history of prolonged immunosuppression, and in patients with a history of PUVA treatment. Use with caution in patients with prior malignancy (use not studied in this population).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Reversible posterior leukoencephalopathy syndrome (RPLS) has been observed (rare). RPLS symptoms include headache, seizures, confusion, and visual disturbances; may be fatal. Monitor; discontinue ustekinumab if symptoms occur and administer appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: Do not use in patients with active tuberculosis (TB). Patients should be evaluated for latent tuberculosis infection with a tuberculin skin test prior to starting therapy. Treatment of latent TB should be initiated before ustekinumab therapy is used. Consider antituberculosis treatment in patients with a history of latent or active tuberculosis if an adequate prior treatment course cannot be confirmed. During and following treatment, monitor for signs/symptoms of active TB.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergen immunotherapy: Use caution in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis; ustekinumab may decrease the protective effect of allergen immunotherapy, which may increase the risk of an allergic reaction to allergen immunotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppressive therapy: Use in combination with other immunosuppressive drugs during psoriasis studies has not been evaluated; use caution. Use in combination with methotrexate during psoriatic arthritis studies did not appear to affect safety or efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &gt;100 kg: May require higher dose to achieve adequate serum levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. <b>Live vaccines should not be given concurrently</b>; inactivated or nonlive vaccines may be given concurrently, but may not elicit a proper immune response. BCG vaccines should not be given 1 year prior to, during, or 1 year following treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phototherapy: Use in combination with phototherapy has not been studied; use caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300199\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6872026\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9514&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">InFLIXimab: Ustekinumab may enhance the immunosuppressive effect of InFLIXimab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867269\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in animal reproduction studies; there are limited data related to the use of ustekinumab in human pregnancy. In general, other agents are preferred for the treatment of plaque psoriasis in pregnant women (Hsu 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Data collection to monitor pregnancy and infant outcomes following exposure to ustekinumab is ongoing. Patients may enroll themselves by calling 1-877-311-8972.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867272\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if ustekinumab is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ustekinumab is a recombinant IgG monoclonal antibody and maternal IgG molecules are known to be present in breast milk; however, systemic exposure to a breastfed infant is expected to be low secondary to the large size of the molecule and the degradation of ustekinumab within in the GI tract. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6868007\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Tuberculosis screening (prior to initiating and periodically during therapy); CBC; ustekinumab-antibody formation; monitor for signs/symptoms of infection, reversible posterior leukoencephalopathy syndrome (RPLS), and squamous cell skin carcinoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6868003\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ustekinumab is a human monoclonal antibody that binds to and interferes with the proinflammatory cytokines, interleukin (IL)-12 and IL-23. Biological effects of IL-12 and IL-23 include natural killer (NK) cell activation, CD4+ T-cell differentiation and activation. Ustekinumab also interferes with the expression of monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-&alpha;), interferon-inducible protein-10 (IP-10), and interleukin-8 (IL-8). Significant clinical improvement in psoriasis and psoriatic arthritis patients is seen in association with reduction of these proinflammatory signalers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6867991\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub> (central compartment): 2.74 L; V<sub>dss</sub>: Crohn disease: 4.62 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 10 to 126 days; Psoriasis: 14.9 &plusmn; 4.6 to 45.6 &plusmn; 80.2 days; Crohn disease: ~19 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 45 mg: 13.5 days; 90 mg: 7 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321916\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Stelara Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">130MG/26ML (26 mL): $1,920.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Stelara Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg/0.5 mL (0.5 mL): $12,350.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Stelara Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg/0.5 mL (0.5 mL): $12,350.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg/mL (1 mL): $24,701.16</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961946\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Stelara (AR, AT, AU, BB, BE, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HK, HN, HR, ID, IE, IL, IS, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity.<i> Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. <i>Gastroenterology.</i> 2017;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/28780013/pubmed\" target=\"_blank\" id=\"28780013\">28780013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galvan-Banqueri M, Marin Gil R, Santos Ramos, B, et al, &ldquo;Biological Treatments for Moderate-to-Severe Psoriasis: Indirect Comparison,&rdquo; <i>J Clin Pharm Ther</i>, 2013, 38(2):121-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/23442134/pubmed\" target=\"_blank\" id=\"23442134\">23442134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsu S, Papp KA, Lebwohl MG, et al, &quot;Consensus Guidelines for the Management of Plaque Psoriasis,&quot; <i>Arch Dermatol</i>, 2012, 148(1):95-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/22250239/pubmed\" target=\"_blank\" id=\"22250239\">22250239</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. <i>J Am Acad Dermatol</i>. 2015;73(4):594-603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/26259989/pubmed\" target=\"_blank\" id=\"26259989\">26259989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonardi CL, Kimball AB, Papp KA, et al, &ldquo;Efficacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Psoriasis: 76-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 1),&rdquo; <i>Lancet</i>, 2008, 371(9625):1665-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/18486739/pubmed\" target=\"_blank\" id=\"18486739\">18486739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimball AB, Papp KA, Wasfi Y, et al, &ldquo;Long-term Efficacy of Ustekinumab in Patients With Moderate-to-Severe Psoriasis Treated for up to 5 Years in the PHOENIX 1 Study,&rdquo; <i>J Eur Acad Dermatol Venereol</i>, 2012 [epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/23279003/pubmed\" target=\"_blank\" id=\"23279003\">23279003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Papp KA, Griffiths CE, Gordon K, et al, &ldquo;Long-Term Safety of Ustekinumab in Patients With Moderate-to-Severe Psoriasis: Final Results From 5 Years of Follow-Up,&rdquo; <i>Br J Dermatol</i>, 2013, 168(4):844-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/23301632/pubmed\" target=\"_blank\" id=\"23301632\">23301632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Papp KA, Langley RG, Lebwohl M, et al, &ldquo;Efficacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Psoriasis: 52-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2),&rdquo; <i>Lancet</i>, 2008, 371(9625):1675-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/18486740/pubmed\" target=\"_blank\" id=\"18486740\">18486740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reddy M, Davis C, Wong J, et al, &ldquo;Modulation of CLA, IL-12R, CD40L, and Il-2R&alpha; Expression and Inhibition of IL-12- and IL-23-Induced Cytokine Secretion by CNTO 1275,&rdquo; <i>Cell Immunol</i>, 2007, 247(1):1-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/17761156/pubmed\" target=\"_blank\" id=\"17761156\">17761156</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandborn WJ, Gasink C, Gao LL, et al, &ldquo;Ustekinumab Induction and Maintenance Therapy in Refractory Crohn&rsquo;s Disease,&rdquo; <i>N Engl J Med</i>, 2012, 367(16):1519-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/23075178/pubmed\" target=\"_blank\" id=\"23075178\">23075178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity.<i> Lancet</i>. 1995;345(8960):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ustekinumab-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stelara (ustekinumab) [prescribing information]. Horsham, PA: Janssen Biotech; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stelara (ustekinumab) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; December 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9514 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9419532\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6867209\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6867212\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6868014\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46146609\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F6867998\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F6867999\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F6868000\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6868009\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F6867211\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9419531\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6868005\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6867268\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6867207\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6867984\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6867273\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6867274\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300199\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6872026\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6867269\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6867272\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6868007\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6868003\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6867991\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321916\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961946\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9514|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ustekinumab-patient-drug-information\" class=\"drug drug_patient\">Ustekinumab: Patient drug information</a></li></ul></div></div>","javascript":null}